Efficacy News and Research

RSS

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

A new analysis of current data indicates that remdesivir does not show efficacy in regulating the severity of the illness.

23 Jun 2021

SARS-CoV-2 Delta variant likely to become dominant in the United States

Researchers have conducted a study showing that the B.1.1.7 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in the UK is now rapidly being displaced as the dominant strain in the United States by the variants of concern B.1.617.2 (Delta) and P.1 (Gamma) that emerged in India and Brazil, respectively.

23 Jun 2021

Cedars-Sinai receives $11.99 million from CIRM to launch ALS clinical trial

Cedars-Sinai has been awarded $11.99 million by California's stem cell agency to launch a clinical trial testing a potential gene and stem cell therapy for amyotrophic lateral sclerosis (ALS).

23 Jun 2021

SARS-CoV-2 infection and transmission in the North American deer mouse

A recent study conducted in Canada reports that the North American deer mouse can be infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from humans.

23 Jun 2021

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.

23 Jun 2021

Natural compound myricetin shows antiviral potential against SARS-CoV-2

New findings from a team of Chinese researchers suggest natural compounds — specifically the flavonoid myricetin — could also be a potential drug candidate for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

23 Jun 2021

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Researchers found antibody levels in mRNA vaccinated individuals varied with age, gender, and previous coronavirus disease (COVID-19) infection.

23 Jun 2021

Vaccine side effects should be viewed as a sign of efficacy, say immunologists

The rapid development of safe and efficacious vaccines against SARS-CoV-2 has offered hope that the global COVID-19 pandemic may soon be under control. However, vaccinations remain incomplete in many developed nations, and lag further still in the developing world.

23 Jun 2021

University Hospitals in Northeast Ohio performs first innovative heart procedure

A University Hospitals (UH) patient is the first in Northeast Ohio to undergo a new, innovative procedure called CCM® therapy. UH is among the first hospitals in the United States and the only hospital in Northeast Ohio to use CCM therapy, delivered by the Optimizer® system, to treat patients suffering from heart failure.

23 Jun 2021

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

A new class of drugs that inhibits a "master switch" involved in the vast majority of cases of mantle cell lymphoma (MCL), a fatal subtype of non-Hodgkin's lymphoma, has been discovered by researchers at Mount Sinai.

22 Jun 2021

Cancer immunotherapy may self-limit its efficacy in fighting tumors, study finds

Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni, Ph.D., assistant professor of physiology & biophysics and member of the Institute for Immunology at the University of California, Irvine.

22 Jun 2021

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

How do you kill tumor cells that can't be targeted? Get their more susceptible neighbors to help.

22 Jun 2021

Study determines the mechanism behind respiratory inflammation and finds effective treatment

Applied Biological Laboratories (Applied Bio), a biopharmaceutical company focused on the respiratory disease market, announced that its study published online in Immunology, Inflammation and Disease was able to determine the mechanism behind respiratory inflammation and treat it effectively with Biovanta(TM), a 100% naturally derived, over-the-counter (OTC) drug for cold, cough and sore throat.

22 Jun 2021

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.

22 Jun 2021

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

A team of scientists from the Pennsylvania State University, USA, recently analyzed the pharmacodynamics and pharmacokinetics of antiviral drug remdesivir using computational models. Based on the study findings, which are yet to be peer-reviewed, the scientists recommend that for effective inhibition of SARS-CoV-2 infection, remdesivir should be used with other antiviral medicines, or its dosing regimen should be optimized to improve bioavailability.

22 Jun 2021

Is liquid chalk an effective disinfectant of SARS-CoV-2 and influenza viruses?

A recent study, published in the American Society for Microbiology’s journal, mSphere, evaluated the use of many liquid chalk products as antiseptics against the transmission of highly pathogenic human viruses such as influenza A virus (H1N1), SARS-CoV-2, (IAV), and norovirus in a mouse norovirus (MNV) model. The researchers applied chalk before or after virus inoculum and determined the recovery of infectious virus to mimic its use in the gym setting.

22 Jun 2021

Researchers screen Chinese herbal medicines and plant compounds for anti-SARS-CoV-2 activity

A review published in Phytotherapy Research discussed the natural anti-SARS-CoV-2 products identified based on in silico prediction. The review’s authors also illustrate the impact of many phytochemicals either alone or in combination with traditional treatments and their potential molecular mechanisms involved in SARS-CoV-2 prevention and treatment.

22 Jun 2021

LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc.

From Iksuda Therapeutics 22 Jun 2021

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

All coronaviruses produce four primary structural proteins and multiple nonstructural proteins. However, the majority of antibody-based SARS-CoV-2 research has focused on the spike and nucleocapsid proteins.

22 Jun 2021

Efficacy News and Research

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

SARS-CoV-2 Delta variant likely to become dominant in the United States

Cedars-Sinai receives $11.99 million from CIRM to launch ALS clinical trial

SARS-CoV-2 infection and transmission in the North American deer mouse

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Natural compound myricetin shows antiviral potential against SARS-CoV-2

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Vaccine side effects should be viewed as a sign of efficacy, say immunologists

University Hospitals in Northeast Ohio performs first innovative heart procedure

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

Cancer immunotherapy may self-limit its efficacy in fighting tumors, study finds

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

Study determines the mechanism behind respiratory inflammation and finds effective treatment

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

Is liquid chalk an effective disinfectant of SARS-CoV-2 and influenza viruses?

Researchers screen Chinese herbal medicines and plant compounds for anti-SARS-CoV-2 activity

LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News